Scholarlink

<p>IgA nephropathy (IgAN) is one of the most common primary glomerular diseases worldwide and is the most common cause of chronic kidney disease (CKD) in China. It lacks recommended treatment in refractory IgAN after conventional therapy. Belimumab, a recombinant human IgG-1λ monoclonal antibody that inhibits the B lymphocyte stimulator, is recommended to treat active lupus nephritis. This report presents a case of a child with severe and refractory IgAN who showed kidney response after belimumab addition combined with conventional therapy. The therapy result was accompanied by decreased plasma cells in peripheral blood. It is the first case showing the benefits of adding belimumab to other immunosuppressive regimens.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The beneficial effect of adding belimumab in severe and refractory IgA nephropathy: a case report

  • 期刊论文

  • 发表日期：

    2025年1月8日

查看全文
  • Youying Mao,
  • Chenxing Zhang,
  • Jing Xu,
  • Chong Liu,
  • Song Guo Zheng,
  • Lei Yin

摘要

IgA nephropathy (IgAN) is one of the most common primary glomerular diseases worldwide and is the most common cause of chronic kidney disease (CKD) in China. It lacks recommended treatment in refractory IgAN after conventional therapy. Belimumab, a recombinant human IgG-1λ monoclonal antibody that inhibits the B lymphocyte stimulator, is recommended to treat active lupus nephritis. This report presents a case of a child with severe and refractory IgAN who showed kidney response after belimumab addition combined with conventional therapy. The therapy result was accompanied by decreased plasma cells in peripheral blood. It is the first case showing the benefits of adding belimumab to other immunosuppressive regimens.